Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: A phase 1 trial Academic Article uri icon


MeSH Major

  • Antibodies, Monoclonal
  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • Antigens, Neoplasm
  • Antineoplastic Agents
  • Leukemia, Myeloid
  • Myelodysplastic Syndromes
  • Myeloproliferative Disorders


  • A multi-institutional, phase 1 dose-escalation trial of lintuzumab (humanized anti-CD33 antibody; SGN-33, HuM195) was performed in patients with CD33-positive myeloid malignancies. In this study, higher doses than previously tested and prolonged duration of treatment for responding patients were evaluated. Over the dose range of 1.5-8 mg/kg/week, lintuzumab was well tolerated, and a maximum tolerated dose was not defined. The most common adverse event was transient chills with the initial lintuzumab infusion (39%). Responses were observed in 7 of 17 patients with acute myeloid leukemia: morphologic complete remission (n = 4), partial remission (n = 2), and morphologic leukemia-free state (n = 1). Of 14 patients with myelodysplastic syndrome or myeloproliferative diseases, 1 patient had major hematologic improvement and 9 patients had stable disease. In contrast to aggressive conventional chemotherapy, lintuzumab was administered in an ambulatory clinic setting with acceptable toxicity.

publication date

  • December 2009



  • Academic Article



  • eng

Digital Object Identifier (DOI)

  • 10.1080/10428190903050013

PubMed ID

  • 19557623

Additional Document Info

start page

  • 1336

end page

  • 44


  • 50


  • 8